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Key points 
 Cyfip1 plays a crucial role for branching of actin filaments and for lamellipodia 
formation. 
 





During platelet spreading, the actin cytoskeleton undergoes rapid rearrangement, forming 
filopodia and lamellipodia. Controversial data have been published on the role of lamellipodia 
in thrombus formation and stability. The WAVE regulatory complex, which has been shown in 
other cells to drive lamellipodia formation by enhancing actin nucleation via the Arp2/3 
complex, is activated by Rac1 interaction with the WAVE complex subunit Cyfip1. We 
analyzed Cyfip1flox/flox Pf4-Cre mice to investigate the role of Cyfip1 in platelet function. These 
mice displayed normal platelet counts and a slight reduction in platelet volume. Activation of 
mutant platelets was only moderately reduced to all tested agonists as measured by αIIbβ3 
integrin activation and P-Selectin surface exposure. However, lamellipodia formation of 
mutant platelets was completely abolished on different matrices. Nevertheless, Cyfip1-
deficient platelets formed stable thrombi on collagen fibers ex vivo and in two models of 
occlusive arterial thrombosis in vivo. Similarly, the hemostatic function and maintenance of 
vascular integrity during inflammation of the skin and lung were unaltered in the mutant mice. 
Investigation of platelet morphology in an induced thrombus under flow revealed that 
platelets rather form filopodia in the thrombus shell, and are flattened with filopodia-like 
structures when in direct contact to collagen fibers at the bottom of the thrombus. We provide 
for the first time direct evidence that platelet lamellipodia formation is not required for stable 
thrombus formation, and that morphological changes of platelets differ between a static 








Circulating platelets are essential players in hemostasis and thrombosis. Upon vascular 
injury, platelets rapidly adhere to exposed extracellular matrix proteins and form a hemostatic 
plug which limits excessive blood loss, but also represents a major pathomechanism of 
ischemic cardio- and cerebrovascular diseases.1 Thrombus formation is a multi-step process. 
At first, platelet tethering is mediated by the interaction of glycoprotein (GP) Ib with 
immobilized von Willebrand factor on exposed subendothelial collagen. This interaction 
enables binding of GPVI to collagen, which in turn initiates cellular activation. Subsequent 
inside-out upregulation of integrin affinity, synthesis of soluble mediators, granule release, 
and coagulant activity contribute to firm platelet adhesion and thrombus growth.2  
The cytoskeleton ensures normal platelet size and shape, and plays a fundamental role for 
platelet function. Upon agonist-induced platelet activation, a rapid rearrangement of the 
cytoskeleton takes place, which results in platelet shape change and contributes to thrombus 
formation and stability.3 In vitro studies have shown that platelets getting in contact with 
immobilized adhesive proteins such as fibrinogen, start to spread and form first finger-like 
protrusions, so-called filopodia, which are finally remodeled to lamellipodia, which are flat, 
undulating cellular protrusions with Arp2/3-mediated orthogonally arrayed short actin 
filaments. A fully spread platelet displays a circumferential zone of orthogonally arrayed short 
filaments within lamellipodia.4 Controversial data have been published on the role of 
lamellipodia in thrombus formation and stability, which were mainly based on inhibitor studies 
or on analyses of platelets with additional functional defects.5-9 A role for the small GTPase 
Rac1 in platelet lamellipodia formation was demonstrated using mice with deletion of Rac1 in 
the hematopoietic system (Mx1-Cre).5,6 However, while it was suggested that Rac1-regulated 
lamellipodia formation might be essential for maintaining integrity of platelet aggregates 
under shear,5 another study showed that Rac1 deficiency leads to a specific GPVI-
dependent PLC2 activation defect, resulting in impaired platelet adhesion and defective 
thrombus formation on collagen under flow. Supplementation with ADP and a thromboxane 
A2 analogue could rescue this defect.6 Further, analysis of mice with a markedly decreased 
expression of the Arp2/3 complex9 revealed no significant defects in the hemostatic function 
or thrombus formation, although mutant platelets were unable to form lamellipodia. However, 
deletion of Arpc2 was not completely successful in megakaryocytes and platelets (>95% 
reduction),9 which could potentially rescue platelet function. Thus, the role of lamellipodia in 
this process is still unclear and direct proof has been lacking. 
The WASp family verprolin-homologous protein (WAVE) regulatory complex is a five-subunit 
protein complex, which includes the proteins WAVE-1/-2/-3, ABI1/2, NAP1 (also known as 
NCKAP1) or NCKAP1L, Cytoplasmic FMR1-interacting protein (Cyfip) 1/2 and HSPC300.10 
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The WAVE complex is per se inactive, but is activated upon interaction of the subunit 
Cyfip1/2 and Rac1-GTP.11 The active WAVE complex interacts with Arp2/3, which in turn is 
crucial for the formation of branched actin filaments. WAVE-1 and -2 are the two major 
isoforms of WAVE in platelets.12 Homozygous disruption of the WAVE1 gene resulted in 
postnatal lethality with an average lifespan of 23.6 days.13 Analysis of platelets of young 
mutant mice (age of 14-20 days) revealed that WAVE-1 plays an important role downstream 
of GPVI.14 WAVE-2-null mice died at embryonic day 12.5 and their in vitro differentiated 
megakaryocytes exhibited spreading defects.15 The Cyfip1 protein is mainly in a complex 
with the WAVE-2 isoform,16-18 however its role for platelet function has not been studied. 
We investigated the role of Cyfip1 in platelet physiology by generating Cyfip1fl/fl Pf4-Cre mice 
specifically lacking Cyfip1 in megakaryocytes and platelets. We demonstrate that Cyfip1fl/fl Pf4-
Cre mice display normal platelet counts, and that activation of their platelets is only moderately 
decreased. However, mutant platelets are unable to form lamellipodia on different matrices, 
making this mouse line a unique model to study the function of platelet lamellipodia. We 
finally provide definite evidence that lamellipodia formation is dispensable for thrombus 
growth and stability, and that morphological changes of platelets differ between a static 
spreading assay and thrombus formation under flow.  
 
Material and Methods  
Animals. Animal studies were approved by the district government of Lower Franconia 
(Bezirksregierung Unterfranken). Male and female mice were analyzed between 4 and 20 
weeks of age. The Cyfip1 flox mouse strain was created from ES cell clone 
(DEPD00521_7_E11) obtained from the NCRR-NIH supported KOMP Repository 
(www.komp.org) and generated by the CSD consortium for the NIH funded Knockout Mouse 
Project (KOMP). Following importation, the ES cells were cultured on a MEF feeder layer.  
Correct targeting of Cyfip1 was confirmed on DNA extracted from the ES cell clone by PCR 
on the 5’ side (CATTCTAACGTTCAAGATCGCAGACCAG and CACAACGGGT 
TCTTCTGTTAGTCC; 7.5kb) and on the 3’ side (CATGTCTGGATCCGGGGGTACC 
GCGTCGAG and GATCTCCTGGTGCGGCATGCAAGC; 7.1kb). The presence of the 
isolated 3’ loxP site was also confirmed by PCR (AAGCAGTCCGTGCTGAGATG and 
GAACCAAGCTCCCAGATTCC; 262bp). Following confirmation of the genotyping of the 
targeted clone, mouse lines were derived by injection of ES cells into C57BL/6J blastocysts. 
After breeding of chimeras, germline offspring were identified by coat color and the presence 
of the modified allele was confirmed with the 3’ loxP primers described above. Mice were 
subsequently crossed with a mouse line expressing Flpe (Tg(ACTFLPe)9205Dym) to delete 
the selectable marker by recombination at the FRT sites.19 Correct removal of the lacZ gene 
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and Neo cassette was confirmed by PCR across the remaining FRT site 
(CTCTTCTTGTGGACCGCATC and CACGGTAGCCTGACAAGAGG; 562bp). To study the 
function of Cyfip1 in platelets, Cyfip1fl/fl mice (supplemental Figure 1A) were intercrossed with 
mice carrying the Cre-recombinase under the platelet factor 4 (Pf4) promoter20 to generate 
platelet- and megakaryocyte-specific Cyfip1-knockout mice. Cyfip1fl/fl Pf4-Cre is further referred 
to as Cyfip1-/-, Cyfip1fl/fl is further referred to as Cyfip1+/+ which served as controls.  
Platelet preparation, immunoblotting, aggregometry, flow cytometry, platelet 
spreading, electron and super-resolution microscopy, bleeding time, clot retraction, ex 
vivo and in vivo thrombus formation, reverse passive Arthus reaction and LPS-
induced inflammation are described in supplemental Material and methods.  
Data analysis. The presented results are mean ± standard deviation from at least two to 
three independent experiments per group, if not stated otherwise. Differences between 
control and knockout mice were statistically analyzed using the Mann-Whitney-U test. P-
values <0.05 were considered as statistically significant: *P< 0.05; **P<0.01; ***P<0.001. 
Results with a P-value > 0.05 were considered as not significant. 
Data sharing statement. Data supplement is available with the online version of this article. 
 
Results  
Cyfip1fl/fl Pf4-Cre mice display normal platelet counts and only moderately impaired 
platelet activation 
We confirmed lack of the Cyfip1 protein in platelet lysates of Cyfip1-/- mice by Western blot 
analysis (Figure 1A, supplemental Figure 1B). WAVE2 expression was reduced in mutant 
platelets, indicating instability of the complex in the absence of Cyfip1, however, expression 
of Rac1, Arpc2 and WAVE1 remained unaltered (Figure 1A, supplemental Figure 1C). 
Cyfip1-/- mice displayed normal blood cell count parameters, including platelet count, and 
only a slight but significant reduction in platelet volume (Figure 1B-C, MPV: Cyfip1+/+ 5.11 ± 
0.16 fL, Cyfip1-/- 4.83 ± 0.07 fL, ***P<.001, supplemental Figure 1D). Expression of prominent 
glycoproteins and platelet ultrastructure were comparable between Cyfip1+/+ and Cyfip1-/- 
mice (supplemental Figures 1E and 2).  
Activation of mutant platelets was only moderately reduced in response to all tested agonists 
as measured by αIIbβ3 integrin activation and P-Selectin surface exposure (Figure 1D-E). To 
test the functional consequences of this moderate activation defect, we performed in vitro 
aggregation studies. Cyfip1-/- platelets aggregated normally to the G protein-coupled agonist 
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thrombin (Figure 1F) and the GPVI-specific agonist collagen-related peptide (CRP) even at 
very low concentrations (Figure 1F). We only observed consistently a delay in onset of 
aggregation in response to collagen. However, the amplitude as a measure for maximum 
platelet aggregation was comparable between control and mutant platelets (Figure 1F). Next, 
we preincubated washed platelets with apyrase (2 U/ml) and indomethacin (10 μM) to 
prevent the effect of second wave mediators, and then activated with high concentrations of 
collagen. We found that Cyfip1-/- platelets aggregated normally at high collagen 
concentrations under these conditions (10 and 20 µg/mL collagen, Figure 1F), excluding a 
selective GPVI signaling defect in Cyfip1-/- platelets as observed for Rac1-deficient platelets.6 
Next, we assessed changes in protein tyrosine phosphorylation upon stimulation with CRP 
and detected a comparable total tyrosine phosphorylation pattern in Cyfip1-/- platelets (Figure 
1G).  
The Arp2/3 complex is activated by the WAVE regulatory complex downstream of Rac1. 
Therefore, we performed activation studies with control platelets in the presence of the 
Arp2/3 inhibitor, CK-666, and the fungal toxin, cytochalasin D, a potent actin polymerization 
inhibitor. Control platelets incubated with CK-666 (50 µM) displayed reduced activation 
similar to the reduction seen with Cyfip1-/- platelets (IIb3 activation: supplemental Figure 
3A; P-selectin exposure: supplemental Figure 3B). Preincubation of platelets with 
cytochalasin D had a stronger effect on agonist-induced activation as compared to Cyfip1-
deficient platelets (supplemental Figure 3). These data suggest that the moderately reduced 
activation of Cyfip1-/- platelets is rather caused by an Arp2/3-related defect than an upstream 
signaling defect. Taken together, lack of Cyfip1 only moderately and non-selectively impairs 
platelet activation, which has no major effect on platelet-platelet interaction.    
Absent lamellipodia formation of Cyfip1-/- platelets on different matrices in static 
spreading assays  
It has been shown that the WAVE regulatory complex drives lamellipodia formation in other 
cell types.21-23 This prompted us to study the role of the WAVE complex subunit Cyfip1 in 
platelet lamellipodia formation. Four consecutive stages of platelet spreading can be 
observed: (I) adhesion of resting platelets, (II) formation of filopodia, (III) a combination of 
filopodia and lamellipodia, and (IV) only lamellipodia. Cyfip1-/- platelets adhered to fibrinogen 
under static conditions, formed filopodia, but strikingly, lamellipodia formation (phases III and 
IV) was completely abolished (Figure 2A-B, supplemental Videos 1 and 2). However, the 
transition from resting platelet to filopodia-forming platelet was unaltered between both 
groups as revealed by live-imaging of platelet spreading (Figure 2C). At the 30 min time 
point, spread mutant platelets were smaller but had an increased perimeter, and formed 
more filopodia with increased length (Figure 2D-G). To compare the defect of lamellipodia 
7 
 
formation of Cyfip1-/- platelets to reagents interfering with actin branching or polymerization, 
we incubated control platelets with different concentrations of CK-666 and cytochalasin D 
prior spreading, and observed that a concentration of 50 µM CK-666 or higher resulted in a 
significant reduction of fully spread platelets (phase IV), however, even at 200 µM CK-666 
approx. 30% of platelets could be observed in phase III (supplemental Figure 4A). 
Nevertheless, this data shows that the spreading defect of CK-666 treated platelets 
resembles to a large extent the phenotype of the Cyfip1-deficient platelets. In contrast, 
platelets were unable to change their shape when actin polymerization was inhibited by 
cytochalasin D (supplemental Figure 4B). These results suggest that Cyfip1-deficient 
platelets cannot form Arp2/3-dependent branched actin filaments, which are necessary for 
lamellipodia formation.  
Therefore, we investigated the localization of Arp2/3 in spread platelets and found that 
Arp2/3 was strongly expressed at the circumferential zone of control platelets (supplemental 
Figure 5). Interestingly, Arp2/3 also localized to filopodia in control and mutant platelets, 
indicating that not altered expression or localization, but impaired Cyfip1-mediated Arp2/3 
activation is causative for abolished lamellipodia formation. To assess this in more detail, we 
analyzed the cytoskeletal organization of spread platelets by platinum replica electron24 
(Figure 3A) and super-resolution microscopy by direct stochastic optical reconstruction 
microscopy (dSTORM)25 (supplemental Figure 6). Orthogonally arrayed short actin filaments 
were formed in the circumferential zone of spread control platelets. In contrast, Cyfip1-/- 
platelets showed only filopodia consisting of parallel bundles of actin filaments (Figure 3A). In 
agreement, Cyfip1-/- platelets were principally able to assemble filamentous actin as we 
determined the F-actin content in resting platelets and in platelets after activation with CRP 
or thrombin by flow cytometry. Only a slightly decreased content was observed in CRP-
activated platelets but not resting or thrombin-activated platelets (Figure 3B). However, the 
F-actin ratio of activated platelets over resting platelets revealed no significant differences, 
demonstrating that mutant platelets can assemble F-actin after activation similar to controls 
(Figure 3B). Next, we tested whether Cyfip1-deficient platelets form lamellipodia on other 
surfaces. Likewise, mutant platelets could not form lamellipodia on collagen IV, laminin and 
CRP and were unable to reorganize actin filaments into short, branched filaments (Figure 
4A-B). 
Lamellipodia are not required for ex vivo thrombus formation  
Next, we tested the role of lamellipodia in thrombus formation in an in vitro system. 
Therefore, we perfused whole blood over a collagen-coated surface in a flow chamber at 
different shear rates (150 s-1, 1000 s-1, 1700 s-1). Interestingly, surface coverage (Figure 5A-
B) and thrombus volume (Figure 5A,C) were comparable between samples from control and 
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mutant mice (supplemental Videos 3 and 4). Kinetics of single platelet adhesion and 
embolization of smaller platelet aggregates appeared normal. Similarly, Cyfip1-/- platelets 
showed effective thrombus compaction under flow (supplemental Video 4) and clot retraction 
in vitro (Figure 5D-E). Video analyses revealed that single platelets at times formed filopodia 
to grab collagen fibers, before they became activated and initiated thrombus formation 
(supplemental Video 5). Surprisingly, we have never observed fully spread platelets 
(equivalent to phase IV platelets in static spreading assay) with circumferential lamellipodia 
under these conditions. These findings were corroborated when we removed the flow 
chamber from the glass coverslip after the experiment and prepared the sample for scanning 
(Figure 6A) and platinum replica (Figure 6B) electron microscopic analyses. Investigation of 
control and Cyfip1-/- platelet morphology showed that in general, platelets form filopodia in 
the thrombus shell (Figure 6A) and are flattened with filopodia structures and parallel actin 
bundles when in direct contact to collagen fibers at the bottom of the thrombus (Figure 6A-B, 
supplemental Figure 7A-B), contrary to the abundant fully spread platelets with 
circumferential lamellipodia observed in a static spreading assay (Figures 2 and 3). Some 
unspread platelets at collagen fibers were found in control and mutant samples and only in a 
few control platelets we could identify small parts of branched actin filaments at the cell 
boundary (supplemental Figure 7A-B). Taken together, these results demonstrate that 
lamellipodia formation is not required for stable thrombus formation ex vivo and that 
morphological changes of platelets differ between a static spreading assay and thrombus 
formation under flow.    
Cyfip1-/- platelets can expose phosphatidylserine on the surface 
A distinct population of highly activated platelets has been described residing close to 
collagen fibers and as patches around a thrombus. These platelets are characterized by 
surface‐exposed phosphatidylserine (PS), which supports coagulation factor complex 
assembly, and hence is a key regulatory event in murine arterial thrombus formation.26,27 To 
test whether Cyfip1-/- platelets can regulate coagulant activity, washed platelets were 
stimulated with ionomycin, a combination of CRP and thrombin or alone, and PS exposure 
was determined by Annexin V binding. While ionomycin efficiently induced PS exposure, 
platelets stimulated with thrombin or CRP alone could hardly bind Annexin V. The 
combination of CRP and thrombin induced PS exposure on more than 40% of control and 
mutant platelets (supplemental Figure 8A-B). Next, we perfused whole blood over 
immobilized collagen and observed that the number and surface coverage of PS-positive 
collagen-adherent platelets were comparable between control and mutant samples 
(supplemental Figure 8C-D). These data show that platelets can regulate coagulant activity 
without the necessity to form lamellipodia. 
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Normal bleeding times, arterial thrombus formation and maintenance of vascular 
integrity in Cyfip1-/- mice 
Next, we analyzed the relevance of lamellipodia structures for in vivo platelet function. 
Bleeding times after tail tip amputation were comparable between control and Cyfip1-/- mice 
(Figure 7A). The application of 20% FeCl3 on the exteriorized mesenteric arterioles of Cyfip1
-
/- mice resulted in comparable platelet adhesion, appearance of first thrombi (Figure 7B-C) 
and time to formation of occlusive thrombi (Figure 7D, supplemental Videos 6 and 7). 
Similarly, thrombus growth was studied in a second model of arterial thrombosis, in which the 
abdominal aorta is mechanically injured and blood flow is monitored by an ultrasonic 
perivascular Doppler flowmeter. In this model, thrombus formation and occlusion of the 
vessel in Cyfip1-/- mice occurred with similar kinetics as in controls (Figure 7E, supplemental 
Figure 9A). Finally, we isolated the aorta and analyzed the shape of single platelets in the 
experimentally-induced in vivo thrombus (Figure 7F, supplemental Figure 9B). Again, we 
could not observe platelets with lamellipodia, but rather platelets which formed filopodia. This 
shows that lamellipodia structures are not required for classical formation of a hemostatic 
plug or a pathological thrombus in vivo.  
It has been reported that inflammation represents an unconventional hemostatic situation in 
which individual platelets are sufficient to prevent bleeding.28 To test whether platelet 
lamellipodia structures play a role in this process, we challenged mice in two different 
models, namely the reverse passive Arthus reaction (intravenous injection of antigen, 
followed by intradermal injection of antibody) and LPS-induced inflammation. As expected, 
when we depleted platelets in mice by injection of an anti-GPIbα antibody, we observed 
severe inflammatory bleeding in the skin (Figure 7G-H) and into the lung (Figure 7I-J), 
demonstrating the importance of platelets to maintain vascular integrity as reported 
previously.29 Finally, control and Cyfip1-/- mice were subjected to the reverse passive Arthus 
reaction of the skin and LPS-induced lung inflammation. Cyfip1-/- mice did not show signs of 
bleeding in these experimental settings, suggesting that platelet lamellipodia formation is 
dispensable for maintaining vascular integrity at sites of acute inflammation (Figure 7G-J). 
 
Discussion 
Static platelet spreading assays, particularly on fibrinogen-coated surfaces, are frequently 
performed as a measure of the contribution of outside-in signaling and cytoskeletal 
rearrangement in platelet function30 as well as readout for functional properties of in vitro 
produced platelets.31-34 In vitro, four stages of platelet spreading can be observed: (I) 
adhesion of resting platelets, (II) formation of finger-like protrusions, called filopodia, (III) a 
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combination of filopodia and plate-like extensions, called lamellipodia, and (IV) only 
lamellipodia. Under dynamic conditions, platelets adhere to the exposed extracellular matrix, 
become activated and thereby change their shape, which is accompanied by the secretion 
and synthesis of several prothrombotic factors, which together contribute to the activation of 
more platelets and finally leads to aggregate formation.  
It has been debated over years whether the stages of in vitro platelet spreading, particularly 
lamellipodia formation, also contribute to platelet adhesion and activation under dynamic 
conditions in vivo. Platelet lamellipodia have been suggested to be important for the initiation 
of thrombus growth when platelets are in direct contact with extracellular matrix components, 
most notably collagen.5,7,8 In contrast, other publications provided indirect evidence that 
lamellipodia formation is not crucial for thrombus formation and hemostasis.6,9,35 However, 
the mouse models of Rac1 and Arp2/3 deficiency displayed severe defects in GPVI 
signaling,6 and platelet production as well as knockout efficiency,9 respectively. In this study, 
we provide for the first time definitive evidence that platelet lamellipodia formation is not 
required for stable thrombus formation ex vivo and in vivo, hemostatic plug formation as well 
as for maintenance of vascular integrity in inflammatory settings (Figures 5-7) by analyzing 
Cyfip1-deficient mice with abolished lamellipodia formation but only minimal side-effects in 
platelet function (Figures 1-4). Moreover, we demonstrate by direct observation that 
morphological changes of platelets differ between a static spreading assay and thrombus 
formation under flow, where platelets only formed filopodia to adhere to collagen fibers 
(supplemental Video 5) and to form a stable thrombus as visualized by scanning electron 
microscopy in an experimentally-induced arterial thrombus (Figure 7F). We could further 
show that control and mutant platelets in direct contact with collagen fibers at the bottom of 
the thrombus were flattened but formed filopodia structures with parallel actin filaments. Fully 
spread platelets with circumferential lamellipodia, as can be observed in the static spreading 
assay (phase IV), were absent under these conditions (Figure 6, supplemental Figure 7). 
However, although platelet lamellipodia are not required for the formation and overall stability 
of thrombi, we cannot exclude that lamellipodia formation might still be important in other 
thrombi-related processes, such as vessel repair. 
Interestingly, it was previously demonstrated that Arp2/3 complex activation is normal in 
platelets lacking WASp and hypothesized that other proteins, probably WAVE2 or cortactin 
or both, activate the Arp2/3 complex.36 We could show that Cyfip1-deficient platelets have a 
reduced WAVE2 expression (Figure 1A) and cannot form Arp2/3-dependent branched actin 
filaments (Figure 3A). Thus, our data strongly suggest for the first time that the WAVE2 
protein/complex regulates Arp2/3 activity in platelets.  
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It was recently shown that collagen-adherent platelets can transform into PS-exposing 
balloon-like structures, which was termed procoagulant spreading and likely contributes to 
hemostatic and thrombotic responses in vivo by amplifying procoagulant responses.37 We 
tested the ability of mutant platelets to expose PS on the surface after stimulation with CRP 
and thrombin in vitro and under dynamic conditions ex vivo, and obtained comparable results 
for control and mutant mice (supplemental Figure 8). Therefore, we suggest that platelets do 
not need to form lamellipodia in order to expose PS on the surface. Hence, the bridging 
mechanism of platelet and coagulation response seems to be intact in Cyfip1-deficient 
platelets, enabling them to initiate thrombus formation.   
However, one open question remains: what is the role of lamellipodia in platelet function? 
There are several possibilities: (I) Lamellipodia structures could be an in vitro phenomenon 
during static platelet spreading. However, this is rather unlikely, since many other cells also 
produce this dense network of branched actin filaments contributing to important cellular 
functions. (II) The platelet machinery to form lamellipodia might be a relic of evolution no 
longer needed for the specialized functions platelets have, and thus dispensable. Until now, 
we cannot exclude either possibility, however, most likely is that (III) platelet lamellipodia play 
an important role in other processes besides the initiation of thrombus formation and 
thrombus stability. These membrane protrusions at the leading edge of cells drive cell 
migration in many physiological and pathological situations.38 Recently, it was reported that 
platelets actively migrate at sites of a formed thrombus.39 The authors concluded from their 
findings that platelet migration might be too slow to contribute to thrombus formation, but 
might play a role in thrombus reorganization and consolidation.39 Our data of the Cyfip1-/- 
mice show that platelet lamellipodia, which are most likely a prerequisite for platelet 
migration, are not important for thrombus formation, supporting the conclusion by Gaertner et 
al. of the dispensable role of platelet migration in thrombus growth. We did not directly 
analyze thrombus reorganization, however, we visualized single platelets in an 
experimentally-induced arterial thrombus and found that platelets exclusively form filopodia 
or filopodia-like structures (Figure 7F). Therefore, we suggest that at least lamellipodia are 
not important in the reorganization of a thrombus. Interestingly, Gaertner and colleagues 
could show that platelets also migrate to sites of infection in order to help trap bacteria and 
clear the vascular surface.39 The authors used platelets from Myh9-/- mice, which are unable 
to migrate,39 however can extend lamellipodia but without stress fiber-like formation.40 It will 
be interesting to investigate whether Cyfip1-deficient platelets with absent lamellipodia 
formation can migrate in vitro and in vivo, and whether Cyfip1 is a key protein in bacteria 
scavenging and bundling at sites of infection. 
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In summary, we show that Cyfip1-deficiency does not alter platelet biogenesis and has no 
major impact on platelet activation, but Cyfip1 plays a crucial role for branching of actin 
filaments and consequently for lamellipodia formation in vitro. We took advantage of this 
unique mouse model and could demonstrate that lamellipodia formation is not required for 
the formation of a hemostatic plug or a thrombus. Moreover, Cyfip1-deficient mice could 
maintain vascular integrity at site of inflammation. Finally, we suggest that megakaryocyte-
/platelet-specific Cyfip1-deficient mice represent a unique mouse system to study the role of 
platelet lamellipodia in other platelet-dependent processes in vivo. Further studies will be 
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Figure 1. Moderately reduced activation of Cyfip1-/- platelets. (A) Expression of indicated 
proteins in control and mutant platelets was assessed by Western blot analysis. GAPDH 
served as loading control (n=3). (B) Platelet count per μL and (C) platelet size given as mean 
forward scatter (FSC) was determined via flow cytometry (n=4, representative for four 
independent experiments). Values are mean ± s.d. ***P<.001. (D) Flow cytometric 
determination of inside-out activation of the αIIbβ3 integrin (JON/A-PE antibody) and (E) 
degranulation-dependent P-selectin exposure (FITC-labelled anti-P-selectin antibody) in 
response to the agonists ADP, U46619 (thromboxane analogue), Thrombin (Thr), collagen 
related peptide (CRP), convulxin (CVX) and Rhodocytin (RC). (n=5, representative for four 
independent experiments); Values are mean ± s.d. **P<.01, ***P<.001. (F) Washed platelets 
from Cyfip1+/+ and Cyfip1-/- mice were activated with the indicated agonists. 2nd wave 
inhibitors: Indomethacin 10 µM, EDTA, Apyrase 2 U/ml (representative curve of at least six 
independent samples). (G) Determination of tyrosine phosphorylation after stimulation with 1 
μg/ml CRP under stirring conditions (1000 rpm) at 37°C. Fifty-microliter aliquots were taken 
at the indicated time points. Samples were blotted on a PVDF membrane and stained using 
the 4G10 antibody. GAPDH served as loading control (n=3).  
Figure 2. Cyfip1-deficient platelets are unable to form lamellipodia on a fibrinogen-
coated surface. (A) Washed platelets were allowed to spread on fibrinogen, following 
fixation at the indicated time points. (n=3, representative for three independent experiments). 
Scale bar: 5 µm. (B) Quantification of the different spreading phases of fixed platelets after 5, 
15 and 30 minutes from differential interference contrast images (Zeiss Axiovert 200 inverted 
microscope (100x/1.4 oil objective, Zeiss)). (C) Phase abundance of live cells over time (WT 
n=58; KO n=32). Quantification of (D) platelet size and (E) platelet perimeter (WT n=100, KO 
n=58) of all Cyfip1+/+ and Cyfip1-/- platelets present in a visual field after 30 min spreading. (F) 
Length and (G) number of filopodia (WT n=58; KO n=32) of live platelets in phase II 
spreading. Values are mean ± s.d. ***P<.001. 
Figure 3. Cyfip1-deficient platelets cannot form branched actin filaments. (A) Platinum 
replica electron microscopic images of the cytoskeleton ultrastructure of platelets spread on 
fibrinogen after 15 min; Scale bars: 1 or 4 µm. (B) F-actin content under resting conditions 
and upon stimulation with CRP or thrombin was assessed by measuring the mean 
fluorescence intensity of bound FITC labeled phalloidin in flow cytometry (left). Ratio of mean 
fluorescent intensity of activated vs. resting samples reflecting F-actin polymerization rates 




Figure 4. Abolished lamellipodia formation of mutant platelets on different matrices. 
(A) Washed platelets were allowed to spread on collagen IV, laminin or CRP for 30 min. 
(n=3) Scale bars: 5 µm. (B) Images of the platelet cytoskeleton ultrastructure on CRP after 
15 min. (n=5) Scale bars: 1 µm.  
Figure 5. Normal ex vivo thrombus formation and clot retraction of Cyfip1-deficient 
platelets. (A) Thrombus formation was assessed on collagen at different shear rates. Shown 
are representative fluorescence pictures of platelets stained with a Dylight-488 anti-GPIX 
antibody. (n=5, representative for three independent experiments) Scale bar: 30 µm. (B) 
Surface coverage and (C) relative thrombus volume were quantified. (D) Clot formation was 
observed over time and (E) residual serum volume was measured (n=3, representative for 
two independent experiments). 
Figure 6. Flattened platelets with filopodia-like structures at the bottom of the 
thrombus. (A) Scanning electron microscopic image of platelets after experimentally-
induced ex vivo thrombus formation on collagen. White arrow indicates a filopodium, black 
arrowhead indicates collagen fiber; Scale bar: 4 µm. (B) Platinum replica of platelets after 
experimentally-induced ex vivo thrombus formation on collagen. White arrow indicates a 
filopodium with unbranched actin filaments; Scale bars: 1 and 2 µm. 
Figure 7. Lamellipodia formation is not required for hemostatic function and arterial 
thrombus formation. (A) A 2-mm segment of the tail tip was cut, and bleeding was 
determined to have ceased when no blood drop was observed on the filter paper. Each 
symbol represents 1 individual. (B) Mesenteric arterioles were treated with 20% FeCl3, and 
adhesion and thrombus formation of fluorescently labeled platelets were monitored by in vivo 
fluorescence microscopy. Representative images are shown. (C) Statistical evaluation of the 
time to appearance of a first thrombus and (D) time to occlusion. (E) The abdominal aorta 
was mechanically injured using forceps (compression for 15 s), and blood flow was 
monitored. Each symbol represents one individual. (F) Scanning electron microscopy of an in 
vivo formed thrombus. (n=4); Scale bar: 2 µm. (G-H) Mice were subjected to the rpA reaction 
to induce local skin inflammation. (G) Representative images are shown and (H) Hb content 
in tissue punch biopsies from inflammatory spots was quantified (n=4, representative for 
three independent experiments). (I) Representative images of bronchoalveolar lavage liquid 
at 4 hours after LPS application. (J) Quantification of the Hb content in bronchoalveolar 
lavage liquid. Platelet depleted animals served as positive control of inflammatory bleeding in 
both models (n=5, representative for three independent experiments). 
